RJA
ZYME icon

Raymond James & Associates’s Zymeworks ZYME Stock Holding History

Raymond James & Associates’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$225K Buy
17,901
+1,019
+6% +$11.1K ﹤0.01% 3568
2024
Q2 		$144K Sell
16,882
-11,405
-40% -$102K ﹤0.01% 3673
2024
Q1 		$298K Sell
28,287
-2,868
-9% -$31.8K ﹤0.01% 3379
2023
Q4 		$324K Sell
31,155
-8,085
-21% -$64.4K ﹤0.01% 3233
2023
Q3 		$249K Sell
39,240
-33,251
-46% -$246K ﹤0.01% 3333
2023
Q2 		$626K Sell
72,491
-20,744
-22% -$186K ﹤0.01% 2791
2023
Q1 		$843K Sell
93,235
-60,917
-40% -$531K ﹤0.01% 2560
2022
Q4 		$1.21M Sell
154,152
-11,781
-7% -$82.8K ﹤0.01% 2319
2022
Q3 		$1.02M Buy
165,933
+4,286
+3% +$25.8K ﹤0.01% 2376
2022
Q2 		$857K Sell
161,647
-7,838
-5% -$47.4K ﹤0.01% 2545
2022
Q1 		$1.11M Sell
169,485
-58,939
-26% -$525K ﹤0.01% 2519
2021
Q4 		$3.74M Sell
228,424
-65,398
-22% -$1.36M ﹤0.01% 1738
2021
Q3 		$8.53M Buy
293,822
+33,158
+13% +$1.1M 0.01% 1148
2021
Q2 		$9.04M Sell
260,664
-16,313
-6% -$518K 0.01% 1131
2021
Q1 		$8.75M Buy
276,977
+101,052
+57% +$4.11M 0.01% 1104
2020
Q4 		$8.31M Sell
175,925
-266
-0.2% -$12.4K 0.01% 1056
2020
Q3 		$8.22M Buy
176,191
+44,513
+34% +$1.53M 0.01% 961
2020
Q2 		$4.75M Buy
131,678
+13,134
+11% +$484K 0.01% 1215
2020
Q1 		$4.21M Buy
118,544
+26,488
+29% +$1.08M 0.01% 1139
2019
Q4 		$4.18M Sell
92,056
-20,387
-18% -$741K 0.01% 1366
2019
Q3 		$2.79M Buy
112,443
+19,007
+20% +$476K ﹤0.01% 1587
2019
Q2 		$2.06M Buy
93,436
+37,712
+68% +$692K ﹤0.01% 1787
2019
Q1 		$902K Buy
55,724
+8,815
+19% +$137K ﹤0.01% 2269
2018
Q4 		$689K Sell
46,909
-3,916
-8% -$51.4K ﹤0.01% 2323
2018
Q3 		$798K Buy
50,825
+11,750
+30% +$168K ﹤0.01% 2396
2018
Q2 		$578K Buy
+39,075
New +$605K ﹤0.01% 2581

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Raymond James & Associates's ZYME Position: Q3 2024 in Review

Raymond James & Associates increased its Zymeworks (ZYME) stake by 6% in Q3 2024, buying an estimated $11.1K and bringing the position to 17,901 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #3568.

Raymond James & Associates first reported a position in ZYME in Q2 2018 and has held it in 26 quarters since. The position peaked at $9.04M in Q2 2021. 163 funds tracked by Wall St. Rank hold ZYME as of Q3 2024.

  • Raymond James & Associates held 17,901 shares of Zymeworks worth $225K as of Q3 2024.
  • Raymond James & Associates bought 1,019 Zymeworks shares in Q3 2024, an estimated $11.1K.
  • Zymeworks made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3568 holding.
  • Raymond James & Associates first reported a position in Zymeworks in Q2 2018 and has held it in 26 quarters since.
  • Raymond James & Associates's Zymeworks position peaked at $9.04M in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Zymeworks as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.